“Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 2, Dec. 2018, p. S90, https://doi.org/10.25251/skin.2.supp.91.